Salmon-calcitonin nasal spray in Paget's disease of bone: preliminary results in five patients.
The effectiveness of Synthetic Salmon Calcitonin (SSCT) administered as a nasal spray was assessed via clinical, biological, and radiological variables in 5 Pagetic patients during a 6 months course therapy, the results show that intranasal administration does not decrease the activity of SSCT in Paget's disease of bone.
D000281:Administration, Intranasal; D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D002116:Calcitonin / Q000008:administration & dosage / Q000627:therapeutic use*; D003404:Creatinine / Q000652:urine; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D008297:Male; D008875:Middle Aged; D010001:Osteitis Deformans / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism; D011859:Radiography
C028815:salmon calcitonin; D002116:Calcitonin; D003404:Creatinine; D000469:Alkaline Phosphatase; D006909:Hydroxyproline